Evidence map›Paper›PMID 28729400›Full record

ArticleMolecular cancer therapeutics2017

Vessel-Targeted Chemophototherapy with Cationic Porphyrin-Phospholipid Liposomes.

Dandan Luo, Jumin Geng, Nasi Li, Kevin A Carter, Shuai Shao, G Ekin Atilla-Gokcumen, Jonathan F Lovell

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Supramolecular co-encapsulation of a photosensitizer and chemotherapeutic drug in cucurbit[8]uril for potential chemophototherapy.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2022
    Article
  9. Lipid-based nanoparticles for photosensitive drug delivery systems.Journal of pharmaceutical investigation · 2022
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Targeting Tumor Endothelial Cells with Nanoparticles.International journal of molecular sciences · 2019
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. IntrabilayerACS nano · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Dandan LuoDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York.
Jumin GengDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York.
Nasi LiDepartment of Chemistry, University at Buffalo, State University of New York, Buffalo, New York.
Kevin A CarterDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York.
Shuai ShaoDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York.
G Ekin Atilla-GokcumenDepartment of Chemistry, University at Buffalo, State University of New York, Buffalo, New York.
Jonathan F LovellDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York. jflovell@buffalo.edu.
University at Buffalo, State University of New York · US

Funding

University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
Light-Triggered Drug Release in Primed Pancreatic TumorsR01EB017270 · NIBIB · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LOVELL, JONATHAN F · 2013 to 2021
$3.5M
Targeting Tumors with Resealable Nanovesicles Permeabilized by NIR LightDP5OD017898 · OD · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LOVELL, JONATHAN F · 2013 to 2017
$1.9M
NCATS NIH HHS UL1 TR001412NIBIB NIH HHS R01 EB017270NIH HHS DP5 OD017898
6 · The paper itself

Abstract

Cationic liposomes have been used for targeted drug delivery to tumor blood vessels, via mechanisms that are not fully elucidated. Doxorubicin (Dox)-loaded liposomes were prepared that incorporate a cationic lipid; 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), along with a small amount of porphyrin-phospholipid (PoP). Near-infrared (NIR) light caused release of entrapped Dox via PoP-mediated DOTAP photo-oxidation. The formulation was optimized to enable extremely rapid NIR light-triggered Dox release (i.e., in 15 seconds), while retaining reasonable serum stability.

Indexed as

Drug Delivery SystemsAnimalsCell Line, TumorCell ProliferationDoxorubicinDrug LiberationFatty Acids, MonounsaturatedHumansInfrared RaysLow-Level Light TherapyMicePancreatic NeoplasmsPhospholipidsPolyethylene GlycolsPorphyrinsQuaternary Ammonium Compounds1,2-dioleoyloxy-3-(trimethylammonium)propaneDoxorubicinFatty Acids, Monounsaturatedliposomal doxorubicinPhospholipidsPolyethylene GlycolsPorphyrinsQuaternary Ammonium Compounds

Identifiers

PMID28729400
PMCPMC5669815
OpenAlexW2737287512

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.